FLASH radiotherapy: a Blink-and-You'll-Miss-It cancer treatment?

NCT ID NCT05724875

Ongoing Disease control Sponsor: Centre Hospitalier Universitaire Vaudois Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares a new type of radiation called FLASH, which delivers the dose in less than a second, to standard radiation for treating two common skin cancers: basal cell carcinoma and squamous cell carcinoma. About 60 patients aged 60 and older who cannot have surgery will receive either FLASH or standard radiation. The goal is to see if FLASH causes fewer severe skin side effects while still controlling the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FLASH radiotherapy (high-dose-rate radiation delivered in a fraction of a second)
What this could lead to: If it works, FLASH could become a standard treatment for skin cancer, offering fewer side effects and shorter treatment times.
What could go wrong: This is a small, early-phase study with only 60 participants. FLASH is still experimental, and it may not prove safer or as effective as standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BASAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

basal cell carcinoma skin squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BASAL CELL CARCINOMA CUTANEOUS SQUAMOUS CELL CARCINOMA

Contacts and locations

Locations

Centre Hospitalier Universitaire Vaudois (CHUV)

Lausanne, Canton of Vaud, 1011, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.